New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Eli Lilly and Company

LLY

Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.

Revenue
+38.6%
EPS
+16.3%
Free cash flow
+21.8%
Total debt
+15.0%

Quarter to September 2026, against a year earlier

1,352.05 0.40 +0.03%
Market cap
$1.27T
P/E
43.9×
Fwd P/E FY26e
42.2×
Dividend yield
0.51%
F-score
7/9
ROIC
26.4%
Net debt / EBITDA
1.2×
Payout ratio
0.2×

Revenue to profit Twelve months to Sep 30, 2026

Of every $100 of revenue, $31.90 was left as profit. Gross margin has risen two quarters running, from 82.8% to 83.6%. What is an income statement?

Revenue to profit, in billions of dollars and as a share of revenue
Revenue86.5100.0%
Cost of revenue−14.1−16.4%
Gross profit72.383.6%
Research & development−15.4−17.8%
Selling, general & admin−12.6−14.6%
Other operating costs−9.5−11.0%
Operating income34.840.3%
Income tax−7.2−8.3%
Net income27.631.9%
RevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue$65.2B$72.2B$79.7B$86.5B
Operating income$26.3B$31.5B$33.6B$34.8B
Net income$20.6B$25.3B$26.7B$27.6B
Net margin (right axis)31.7%35.0%33.5%31.9%
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Revenue

+8 more TTM periods

65,179.00 72,249.00 79,665.00 86,461.00
Gross Profit
54,127.00 59,845.00 66,441.00 72,312.00
Operating Income
26,302.00 31,522.00 33,633.00 34,814.00
EBT
25,731.00 31,125.00 33,595.00 34,768.00
Income after Tax
20,640.00 25,277.00 26,711.00 27,579.00
Net Income Common
20,640.00 25,277.00 26,711.00 27,579.00
EPS (Diluted)
22.95 28.15 29.80 30.81
Shares (Diluted, Weighted)
899.63 898.45 896.93 895.58
Gross Margin
83.04% 82.83% 83.40% 83.64%
EBIT Margin
40.35% 43.63% 42.22% 40.27%
Net Profit Margin
31.67% 34.99% 33.53% 31.90%
Free Cash Flow Margin
13.77% 16.36% 22.83% 22.74%
EBITDA
28,299.00 33,565.00 35,732.00 36,988.00
EBIT
26,302.00 31,522.00 33,633.00 34,814.00

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026